US 11,986,470 B2
Methods of treating prostate cancer
Marco Gottardis, Princeton, NJ (US); Rebecca Hawkins, Harleysville, PA (US); Linda A. Snyder, Pottstown, PA (US); and Douglas H. Yamada, Philadelphia, PA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Sep. 13, 2023, as Appl. No. 18/466,547.
Application 18/466,547 is a continuation of application No. 17/989,329, filed on Nov. 17, 2022.
Application 17/989,329 is a continuation of application No. 17/528,017, filed on Nov. 16, 2021.
Application 17/528,017 is a continuation of application No. 16/131,772, filed on Sep. 14, 2018, granted, now 11,207,311, issued on Dec. 28, 2021.
Application 16/131,772 is a continuation of application No. 15/663,082, filed on Jul. 28, 2017, abandoned.
Claims priority of provisional application 62/369,239, filed on Aug. 1, 2016.
Claims priority of provisional application 62/368,466, filed on Jul. 29, 2016.
Prior Publication US 2024/0000766 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/454 (2006.01); A61K 9/00 (2006.01); A61P 13/08 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/454 (2013.01) [A61K 9/0053 (2013.01); A61P 13/08 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)] 22 Claims
OG exemplary drawing
 
1. A method of treating metastatic castration-sensitive prostate cancer in a human in need of such treatment comprising administering to the human a pharmaceutically acceptable amount of niraparib or a salt thereof, wherein the human is carrying at least one DNA repair anomaly in a gene selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, and BRIP1.